Read more here:
Ultimovacs Announces Positive 24-month Follow-up Data from Phase I UV1 Cancer Vaccine-Pembrolizumab Combination Study in Metastatic Melanoma

Related Post

Leave a comment

Your email address will not be published. Required fields are marked *


Refresh